Targeted therapy comes of age in scleroderma

This publication has 35 references indexed in Scilit:

• Activation of Key Profibrotic Mechanisms in Transgenic Fibroblasts Expressing Kinase-deficient Type II Transforming Growth Factor-β Receptor (TβRIIΔk)
  Published by Elsevier ,2005
• Correlation of the degree of dyspnea with health‐related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: Results from the scleroderma lung study
  Arthritis & Rheumatism, 2005
• The rationale behind autologous autoimmune hematopoietic stem cell transplant conditioning regimens: concerns over the use of total-body irradiation in systemic sclerosis
  Bone Marrow Transplantation, 2004
• Mammalian Target of Rapamycin Positively Regulates Collagen Type I Production via a Phosphatidylinositol 3-Kinase-independent Pathway
  Journal of Biological Chemistry, 2004
• A modified model of graft‐versus‐host–induced systemic sclerosis (scleroderma) exhibits all major aspects of the human disease
  Arthritis & Rheumatism, 2004
• A study of the prevalence of systemic sclerosis in northeast England
  Rheumatology, 2004
• Genome‐wide association study for regions of systemic sclerosis susceptibility in a Choctaw Indian population with high disease prevalence
  Arthritis & Rheumatism, 2003
• Analysis of systemic sclerosis in twins reveals low concordance for disease and high concordance for the presence of antinuclear antibodies
  Arthritis & Rheumatism, 2003
• Endothelin and endothelin receptor antagonists in systemic rheumatic disease
  Arthritis & Rheumatism, 2003
• Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled study
  The Lancet, 2001